The Union Health Ministry issued an advisory on 16 September 2026 to all States and Union Territories on the regulation of stem cell therapy in India. The advisory limits stem cell treatment as standard care to disease conditions specifically approved by the Ministry of Health and Family Welfare.
Stem Cell Therapy as Clinical Care
Stem cell therapy uses stem cells, which are undifferentiated cells capable of self-renewal and differentiation into specialised cell types. In India, stem cell treatment can be offered as standard care only for approved indications notified by the Ministry of Health and Family Welfare.
For Autism Spectrum Disorder, the therapeutic use of any type of stem cell is restricted to duly approved clinical trials. Clinical use outside approved indications is not permitted under the current advisory framework.
Regulatory Framework in India
The National Guidelines for Stem Cell Research, 2017, were issued jointly by the Indian Council of Medical Research and the Department of Biotechnology. These guidelines govern stem cell research, clinical trials, and related ethical requirements in India.
The National Medical Commission issued an advisory on 5 September 2026 on the same subject. It stated that unauthorised administration, prescription, promotion, or advertisement of stem cell therapy beyond approved indications constitutes professional misconduct.
Legal Basis and Penalties
The new regulatory position follows a Supreme Court judgment delivered on 30 January 2026 in Yash Charitable Trust & Ors. v. Union of India & Ors. The Ministry has directed States and Union Territories to circulate the Court’s directions to state and district regulatory authorities and to clinical establishments.
Non-compliance can attract action under Regulation 7.22 of the Indian Medical Council Regulations, 2002. It can also trigger proceedings under Sections 32 and 40 of the Clinical Establishments Act, 2010, including cancellation of registration and financial penalties.
Important Facts for Exams
- Stem cells are classified by their ability to differentiate into multiple specialised cell types.
- The Indian Council of Medical Research and the Department of Biotechnology jointly issued the National Guidelines for Stem Cell Research, 2017.
- The Clinical Establishments Act, 2010, provides for regulation of clinical establishments and penalties for non-compliance.
- Professional misconduct in medical practice in India is linked to the Indian Medical Council Regulations, 2002.
